NEWS & INSIGHTS

Gene therapies offer the promise of a one-and-done treatment for debilitating chronic disease—but payers still have lots of questions—from patient selection to duration of response. In this Clinical Leader article, Jeremy Schafer, PharmD, MBA, Senior Vice President of specialty solutions at Precision for Value, describes how well-designed clinical trials can answer these questions.

To read the full article, click here

In this article featured in the Journal of Clinical Pathways, Precision experts review both the financial and quality results of accountable care organizations (ACOs) and their implications for other payers.

(more…)

In a featured article for PM360, Precision’s Ross Maclean and Phil Cyr identify three themes and eight interrelated factors which, if overlooked, can negatively impact a launch. In short, prescribers remain Very Important People in a launch, facing challenges around Vulnerability, Incentives, and Personalization.

(more…)

In an article by Jeremy Schafer, learn why rare disease treatments are no longer safe from formulary exclusion lists and ways manufactures can lessen the risk of being on the list. (more…)

In an article for STAT, Ami Gopalan touches on CVS Health’s latest effort to nudge drug makers to reduce launch prices to a reasonable level. (more…)

The FDA and the US Department of Health and Human Services published final guidance on the presentation of health care economic information (HCEI) and preapproval information exchange (PIE). This is a new opportunity for manufacturers to engage with payers around cost-effectiveness. Precision’s Jeremy Schafer views it from the manufacturer’s perspective in his article for KNect365. (more…)

In response to the increase in value-focused care, vertical integration among payers and pharmacy benefit managers has increased as well, but what does this mean for manufacturers? (more…)

Prior authorization (PA) is a time-consuming and costly burden on healthcare providers. With an increase in specialty medication spending, accounting for 70% of total drug spend, PAs are expected to become more stringent and restrictive. Marylou Buyse and Charline Shan share their insight and explore how the vertical integration mergers might impact PA for the better.

(more…)

A new study by Senior Director, Policy & Economics Julia Thornton Snider, PhD, was recently published in the medical journal Vaccine. (more…)

Challenges persist in measuring value in healthcare, and individual healthcare decision makers need personalized information about value to make informed choices. Precision’s Mark Linthicum, Jennifer Bright, and Jason Shafrin explore an open-source modeling approach to value assessment in an article for Journal of Clinical Pathways.

(more…)